BRCA2 and ovarian cancer: Because increased STAT3 signaling has previously been reported in paclitaxel- and cisplatin-resistant ovarian cancer cells (14, 16), we established Olaparib-resistant BRCA-wildtype A2780 (A2780 Resistant), OVCAR8 (OVCAR8 Resistant), and BRCA2-mutated PEO1 (PEO1 Resistant) cell lines as described previously (22) to investigate the potential role of STAT3 in PARPi resistance.